Levetiracetam NDC 76282-248

NDC codes

FDA NDC Directory

Product NDC (as listed)76282-248Labeler and product segments. Claims need a package NDC.

Product NDC at billing width76282-0248Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
76282-248-12	76282024812	120 TABLET in 1 BOTTLE (76282-248-12)Marketed from Jan 15, 2009

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Levetiracetam
Generic name (nonproprietary): levetiracetam
Active ingredients: Levetiracetam — 750 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Exelan Pharmaceuticals, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 078234
Marketing start: Jan 15, 2009
Listing expires: Dec 31, 2026
Other FDA classes: Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
Identifiers: Product ID 76282-248_b044e723-e969-45fa-a4e6-159bfb65267aSPL ID b044e723-e969-45fa-a4e6-159bfb65267aSPL set ID 28c0e61e-1af9-410a-9fa9-b71bf99a776bRxCUI 311288, 311289, 311290UNII 44YRR34555UPC 0376282248127, 0376282247120, 0376282246123

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N476282024812 followed by a unit qualifier and the quantity

Package 76282-0248-12. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 29, 2018.

Indications (excerpt from the label)

Levetiracetam tablets, USP are antiepileptic drug indicated for adjunctive therapy in the treatment of: Partial onset seizures in patients 4 years of age and older with epilepsy ( 1.1 ) Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy ( 1.2 ) Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy ( 1.3 ) 1.1 Partial Onset Seizures Levetiracetam tablets, USP are indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy. Information describing the use of levetiracetam in pediatric patients less than 4 years of age a…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 078234

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 078234
Product	Strength	Form · route	Labeler	Product NDC
Levetiracetam	Levetiracetam 250 mg/1	TabletOral	Exelan Pharmaceuticals, Inc.	76282-246
Levetiracetam	Levetiracetam 500 mg/1	TabletOral	Exelan Pharmaceuticals, Inc.	76282-247